(NASDAQ: NYXH) Nyxoah Sa's forecast annual revenue growth rate of 178.03% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 10.77%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.4%.
Nyxoah Sa's revenue in 2026 is $6,556,976.On average, 11 Wall Street analysts forecast NYXH's revenue for 2026 to be $1,122,025,810, with the lowest NYXH revenue forecast at $823,131,801, and the highest NYXH revenue forecast at $1,415,250,557. On average, 10 Wall Street analysts forecast NYXH's revenue for 2027 to be $2,725,188,001, with the lowest NYXH revenue forecast at $2,281,220,954, and the highest NYXH revenue forecast at $3,166,564,459.
In 2028, NYXH is forecast to generate $5,781,145,532 in revenue, with the lowest revenue forecast at $5,332,109,940 and the highest revenue forecast at $6,189,257,313.